TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: current back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with anaesthesia during perineal repair
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal velocity on the modified 20-m shuttle test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CAL (Coronary Artery Lesions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fever control within 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum immunoglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma BNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lactate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of implantations in relation to the coronal mechanical axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual bother score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: higher-level mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: attention processes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BBHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of CMV disease
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of posttransplant lymphoproliferative disease
Endpoint domain: Adverse events/effects
Primary endpoint: NRS-scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in oxygen extraction ([Formula: see text]o2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of intubation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma noradrenaline concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT-proBNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of major adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: weekly average number of eDiary-recorded RP attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive status (Mini-Mental State Examination)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Days in the intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Initiation of breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAIS (skin turgor and overall vitality)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: OCT (epidermal and dermal thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: plaque progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: constrictive remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: daily nursing workload for glucose control
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean daily costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Use of emergency contraception within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Convenience of emergency contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bacterial colony counts in the operative field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Receipt of mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Skin tear incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severe post-exertional malaise
Endpoint domain: Adverse events/effects
Primary endpoint: Verbal and visual pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total administered morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary care follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need for allogeneic transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: best-corrected visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeon anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician‐Administered PTSD Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Assessment of Functioning score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain relief measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lequesne index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (SF-36 and DLQI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: six-minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnoea score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower production of blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: gain of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac-related hospitalization rate
Endpoint domain: Mortality/survival
Primary endpoint: apparent clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution (V/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first-order absorption constant (ka)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-peritoneal fat layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical malaria infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: T-AOC level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell proliferation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboembolic or bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving fetal asystole within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slowing disability progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of Th1/Th2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Family functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social recovery
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: anxiety levels during speech 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle area change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of early ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Median IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Median baseline visual field mean deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Patient-oriented composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLQI overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VQ-Dermato score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: P300 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 35% or more SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% or more reduction in TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG amplitude versus dynamic torque relationships
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: QT interval length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ventricular extrasystoles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apo-B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DTS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PHQ‐9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-year TLF
Endpoint domain: Mortality/survival
Primary endpoint: PoCE
Endpoint domain: Mortality/survival
Primary endpoint: CI-TLR
Endpoint domain: Mortality/survival
Primary endpoint: unplanned pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Insomnia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of neonatal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of vagal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Current density changes in the alpha2 band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Platelet function as measured by AA-induced light transmittance aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Resistance to aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dose-related platelet response to aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mid-arm circumference (MAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of clotting factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Partial thromboplastin time (PTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: peak knee adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moment arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V(max) and Vm measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality from cardiogenic shock
Endpoint domain: Mortality/survival
Primary endpoint: self-report of multiple STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self-report of STI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Grade≥2 acute urinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain with tenaculum placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe SG
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of SG
Endpoint domain: Adverse events/effects
Primary endpoint: amount of debris produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plaque progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Size of calcium deposits decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medication dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in defeatist beliefs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive self-concept
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: suPAR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Global scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion in long-term institutional care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in use of community services and expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost differences between study patients and controls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Failure rate for detecting correctable venous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total effective rate of Jiannao Yizhi Granule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral E-wave deceleration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of remaining in the study (asthma stability criteria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 of propofol for loss of lash reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regional arm fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: regional arm bone free-fat free mass (BF-FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total body BF-FFM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of fentanyl absorbed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of genetic findings supporting the diagnosis of hereditary CRCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Privacy concerns after receiving CRCP results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to change life insurance after receiving results
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Disturbance from wearing CPAP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calgary sleep apnea quality of life index (SAQLI) total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FGF‐23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Left ventricular mass index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temperature rhythm changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in VTE prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety in VTE prophylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of symptomatic antibiotic-treated UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in microbiologically proven UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Absolute reduction in UTI episodes over 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Harsh discipline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Net cost saving per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per death prevented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful treatment
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in signs and symptoms of OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cartilage degradation marker (C-terminal crosslinking telopeptide of type II collagen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DASS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continence rates at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction at 5 years
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peri-operative myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term mortality
Endpoint domain: Mortality/survival
Primary endpoint: Composite of morbidity and mortality endpoints
Endpoint domain: Mortality/survival
Primary endpoint: HIV replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma HIV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean fluid flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall rosacea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: investigator and patient overall efficacy assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: T4SS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal congestion relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iTNSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating MCP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte proportions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD11b expression on monocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probing pocket depth (PPD) ≥7 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of high-grade postoperative complications (PC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for a percutaneous postoperative drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic properties of FF/VI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of dietary supplements for vasomotor symptoms
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-reported health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Morbidity rate
Endpoint domain: Mortality/survival
Primary endpoint: Major surgical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: low back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral rates for evidence-informed interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Body mass index (BMI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes